About Amarantus BioScience Holdings
Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.
The Company’s lead therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia, one of the most difficult problems facing patients with Parkinson’s disease. Eltoprazine is currently in a Phase 2b clinical trial with results from the study expected in 2016. Eltoprazine is also being evaluated for the treatment of adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression.
Amarantus recently completed the acquisition of Cutanogen Corporation (Cutanogen) from Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd. Cutanogen has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute (ESS). ESS is a full thickness skin replacement product prepared from autologous (patient's own) tissue-engineered skin cells in development for the treatment of severe burns. ESS received orphan drug designation from the FDA for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting. Amarantus expects to commence a Phase 2 study of ESS in the U.S. in the third quarter of 2015. Amarantus is also developing MANF (mesencephalic-astrocyte-derived neurotrophic factor), which was discovered by the company’s own discovery platform, PhenoGuard. MANF is being developed for the treatment of brain and ophthalmic disorders and has received Orphan Drug Designation from the FDA and the European Medicines Agency (EMA) for the treatment of Retinitis Pigmentosa.
The company’s diagnostics division, Amarantus Diagnostics is dedicated to the development and commercialization of neurology diagnostic products. The company’s lead diagnostic product, LymPro Test® is a blood based assay to diagnose Alzheimer’s disease and is approved for investigational use only to be used in biotech and pharmaceutical clinical trials.
Amarantus Diagnostics is also developing MSPrecise®, a proprietary, next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation.
The company is active exploring a number of strategic options for Amarantus Diagnostics, including a potential spin-off, to derive the full value of its premier neuro-diagnostics business.